Skip to the contents
Disease profiles
×
Reported cases
From
To
Disease situation (Filter animal category)
From
To

Geographical distribution

Based on official disease reports to the WOAH

CCPP is a disease listed in the World Organisation for Animal Health (WOAH) Terrestrial Animal Health Code and must be reported to the WOAH. The map to the right displays outbreak points reported to the WOAH early warning system since 2005.

As described in the WOAH Terrestrial Animal Health Code, the WOAH early warning system includes immediate notifications and follow-up reports on:

  • First occurrences of a listed disease,
  • Recurrence of an eradicated listed disease,
  • First occurrences of new strain of a pathogenic agent of a listed disease,
  • Recurrence of an eradicated strain,
  • Sudden and unexpected changes in the distribution or increase in incidence or virulence of, or morbidity or mortality caused by the pathogenic agent of a listed disease
  • Occurrence of a listed disease in an unusual host species.

Countries are coloured according to the available information regarding their stable disease situation (disease status legend). This information is provided by countries through the WOAH monitoring system, which is a different reporting channel.
Immediate notifications (points) and disease status (country/region colours) are reported to the WOAH in different spatial and temporal scales, and therefore are displayed in the map as layers which can be filtered independently.

Last updated at: 2023-01-30

For more up to date reports, visit the original data source: WOAH-WAHIS.

Disease

Animal Health Impact

A summary of the disease in animal hosts is given in the WOAH Technical disease card.

The panel to the right summarizes all evidence collected by EFSA from published studies describing natural infections with this agent (as opposed to experimental infections, summarized in the next section). Scroll down to see summaries of the data collected according to the type of field investigation context. The following study context categories are considered, and summaries are shown in a dedicated section of the panel to the right if any references in the category were included in the literature review:

  • Outbreak investigation
  • Passive surveillance (reports of specific surveillance activities following reported cases)
  • Proof of disease freedom (investigations to confirm disease absence)
  • Observational study (case-control or cohorto studies)
  • Active surveillance (active testing of animals and search for cases)
  • Survey (designed sampling and testing of animals)

EFSA conducts regular systematic literature reviews covering studies investigating natural infections with this agent, and published in peer-reviewed literature in English since 1970.

You can download all data collected through systematic literature review here. Data fields are explained in this read-me file.

*The review was last updated in January 2022. The complete list of references is available for download here. If important references to primary studies are missing, contact animal-diseases@efsa.europa.eu. The full review protocol can be downloaded here.

Experimental Inf.

A summary of the disease in animal hosts is given in the WOAH Technical disease card.

The panel to the right summarizes all evidence collected by EFSA from published experimental infection studies describing the health effects of this pathogen in host animal species. Scroll down through the content.

Summaries of available scientific evidence are provided concerning:

  • Host species
  • Start of clinical signs (incubation period)
  • Duration of clinical signs
  • All diverse types of clinical signs reported in the different host species
  • Case fatality
  • Meta-analysis of the reported duration of observable clinical signs, accounting for censoring in the experimental infection study groups

EFSA conducts regular systematic literature reviews covering all experimental infections published in peer-reviewed literature in English since 1970.

You can download all data collected through systematic literature review here. Data fields are explained in this read-me file.

*The review was last updated in January 2022. The complete list of references is available for download here. If important references to primary studies are missing, contact animal-diseases@efsa.europa.eu. The full review protocol can be downloaded here.

Public Health

Humans are not susceptible, and therefore there is no direct impact on public health (WOAH Technical disease card).

Agent

Taxonomy

Family: Mycoplasmataceae

Genus: Mycoplasma

Species: Mycoplasma capricolum subsp. Capripneumoniae

Agent characteristics

Refer to the WOAH Technical disease card for a key summary of the bacterium characteristics.

Bacteria survival outside living hosts

The panel to the right summarizes all evidence collected by EFSA from published experiments on pathogen survival. Scroll down through the content.

Summaries of available scientific evidence are provided concerning:

  • All the different matrices in which agent survival was studied.
  • Survival plots indicating the maximum number of days the virus was detected in different matrices under different conditions (temperature)
  • Survival plots indicating the maximum number of days the bacterium was detected in different matrices under different conditions (temperature)
  • Half-life studies which documented virus viability decay over time under different temperatures
  • Meta-analysis of the reported virus survival period for matrices in which a sufficient number of studies were found

EFSA conducts regular systematic literature reviews covering pathogen survival experiments published in peer-reviewed literature in English since 1970.

You can download all data collected through systematic literature review here. Data fields are explained in this read-me file.

*The review was last updated in January 2022. The complete list of references is available for download here. If important references to primary studies are missing, contact animal-diseases@efsa.europa.eu. The full review protocol can be downloaded here.

Transmission

Refer to the WOAH Technical disease card for a key summary of the disease transmission and epidemiological parameters.

The panel to the right summarizes all evidence collected by EFSA from published experimental infection studies describing host infectiousness. Scroll down through the content.

Summaries of available scientific evidence are provided concerning:

  • Evidence of Host-host transmission
  • Evidence of transplacentary transmission
  • Meta-analysis of the reported duration of the infectious period, accounting for censoring in the experimental infection study groups
  • Data for all animal matrices in which agent presence was demonstrated.

EFSA conducts regular systematic literature reviews covering all experimental infections published in peer-reviewed literature in English since 1970.

You can download all data collected through systematic literature review here. Data fields are explained in this read-me file.

*The review was last updated in January 2022. The complete list of references is available for download here. If important references to primary studies are missing, contact animal-diseases@efsa.europa.eu. The full review protocol can be downloaded here.

Diagnosis

WOAH-prescribed tests for international trade include:the commercial competitive enzyme-linked immunosorbent assay (ELISA) and in-house indirect ELISA (WOAH, Terrestrial Manual)

EFSA conducts regular systematic literature reviews covering peer-reviewed literature in English since 1970, covering diagnostic tests approved for use in the European Union (EU).

Data were collected from all evaluations of performance of those tests which provided sensitivity or specificity (or enough data to estimate those needed to be provided). You can browse through the data collected scrolling the panel to the right.

Two main types of performance evaluation studies are reported in literature:

  • (i) those which evaluated test performance using a set of samples from animals with known infectious status (samples from truly infected and non-infected animals);
  • (ii) those which compared test performance against a gold standard test, assuming the result of that test (positive or negative) to represent true infection status.

Results for these two types of evaluations are presented separately.

We have chosen not to aggregate and summarize the results because the study conditions can vary greatly. Instead, we present below the results for all the articles retrieved from the literature individually, grouped by type of test and, when relevant, animal species.

You can download all data collected through systematic literature review here. Data fields are explained in this read-me file.

The review was last updated in January 2022. The complete list of references is available for download here. If important references to primary studies are missing, contact animal-diseases@efsa.europa.eu. The full review protocol can be downloaded here.

Vaccination

CCPP vaccines are not used within the European Union.

EFSA conducts regular systematic literature reviews covering all vaccine efficacy studies published in peer-reviewed literature in English since 1970, when evaluating vaccines approved for use in the European Union. The next update of the SLR for vaccines is scheduled to be carried out in 2023.

Picture on the right: Congerdesign. Public domain.

Treatments

In accordance with the Animal Health Law (AHL) in the EU (see next tab), all animals on infected goat holdings should be culled to prevent further spread of the bacteria. Specific treatments for CCPP are not available and not compliant with the AHL.

Picture on the right: International Livestock Research Institute (ILRI)/Yvane Marblé. CC-0

Animal Health Law Risk Assessments

CCPP is listed as a category A diseases in the "Animal Health Law" - Regulation (EU) 2016/429 of the European Parliament and of the Council of 9 March 2016 on transmissible animal diseases and amending and repealing certain acts in the area of animal health.

EFSA has published a series of Scientific Opinions on risk assessment of several scientific topics within the framework of AHL, upon request by the European Comission (EC). You can browse through the AHL legislations and EFSA’s Scientific Opinions on the right panel.

Other Risk Assessments

EFSA regularly carries out risk assessments to support risk managers with their decision making on the prevention and control of diseases. Risk assessments of relevance for this disease are listed in the right panel

Acknowledgments

The CoVetLab consortium has been responsible for the systematic literature reviews since 2015, and has delivered story maps to EFSA since 2021. Partners are: Swedish National Veterinary Institute (SVA, Sweden); Wageningen Bioveterinary Research (WBVR, The Netherlands); Animal and Plant Health Agency (APHA; UK) and the University of Surrey (UK).

Geographical distribution data has been kindly provided by the World Organisation of Animal Health (WOAH). WOAH-WAHIS (WOAH World Animal Health Information System) is the original source of these data.

EFSA thanks the following experts for their specific contribution to this story map:

  • Expert name1
  • Expert name2

References

The list of references displayed in this storymap is available on the right panel.

You can also download the complete list of references for each of the seven specific knowledge domains for which EFSA carries out systematic literature reviews regularly (living reviews):